XML 86 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
 1 Months Ended 12 Months Ended
Jul. 31, 2014
Feb. 28, 2014
Dec. 31, 2014
Milestone
Dec. 31, 2013
Dec. 31, 2012
May 31, 2012
Jan. 31, 2012
Jan. 31, 2014
Jun. 30, 2014
Revenue Recognition, Milestone Method [Line Items]                  
Non-refundable payment received             $ 30bdsi_NonRefundablePaymentReceived    
Potential milestone payments on intellectual property rights     15bdsi_PotentialMilestonePaymentReceivableIntellectualProperty            
Potential milestone payment received, clinical development     20bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment            
Potential payment upon filing and acceptance     10.0bdsi_PotentialPaymentsUponFilingAndAcceptance            
Potential milestone payment receivable upon regulatory approval     50bdsi_PotentialMilestonePaymentReceivableRegulatoryApproval            
Payment receivable on achievement of potential sales milestones     55bdsi_PaymentsReceivableOnAchievementOfPotentialSalesMilestones            
Number of potential sales milestones     4bdsi_NumberOfPotentialSalesMilestones            
Recognized up-front payment allocated to the license     15.6bdsi_RecognizedUpFrontPaymentAllocatedToLicense            
Recognized up-front payment to clinical trial material and development services     14.4bdsi_RecognizedUpFrontPaymentToClinicalTrialMaterialAndDevelopmentServices            
Upfront payment     30bdsi_UpfrontFeesAssignedToDeliverablesConsistingOfIntellectualPropertyComponentValue            
Estimated amount recognized against clinical services deliverable     2.5bdsi_EstimatedAmountRecognizedAgainstClinicalServicesDeliverable 6.3bdsi_EstimatedAmountRecognizedAgainstClinicalServicesDeliverable 5.2bdsi_EstimatedAmountRecognizedAgainstClinicalServicesDeliverable        
Deferred revenue from research and development activities     0.4bdsi_DeferredRevenueResearchAndDevelopment            
Term of Endo Agreement     10 years            
Extended patent on drug delivery technology     2020 to 2027            
Potential milestone payments on issuance of patent           15bdsi_PotentialMilestonePaymentOnIssuanceOfPatent      
Milestone payment regarding licensing agreement 10bdsi_AggregateMilestonePaymentsReceivedUnderLicenseAgreement 10bdsi_AggregateMilestonePaymentsReceivedUnderLicenseAgreement              
Total rate of reimbursable contractor costs borne     50.00%bdsi_ReimbursementOfCostIncurred            
Deferred revenue recognized during the period     5.4us-gaap_DeferredRevenueRevenueRecognized            
Clinical Trials One [Member]                  
Revenue Recognition, Milestone Method [Line Items]                  
Potential milestone payment received, clinical development               10bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsOneMember		  
Clinical Trials Two [Member]                  
Revenue Recognition, Milestone Method [Line Items]                  
Potential milestone payment received, clinical development                 10bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsTwoMember
Endo License and Development Agreement [Member]                  
Revenue Recognition, Milestone Method [Line Items]                  
Deferred revenue from research and development activities     $ 12.7bdsi_DeferredRevenueResearchAndDevelopment
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		            
Total rate of reimbursable contractor costs borne     50.00%bdsi_ReimbursementOfCostIncurred
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		            
Reimbursement rate of costs by Endo to the company as per agreement     100.00%bdsi_PercentageOfReimbursementExpenses
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		            
Percentage of credit against potential future milestones     50.00%bdsi_PercentageOfCreditAgainstPotentialFutureMilestone
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember